KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Prepaid Assets: 2020-2024

Historic Prepaid Assets for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $67.1 million.

  • AbCellera Biologics' Prepaid Assets rose 206.68% to $133.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.0 million, marking a year-over-year increase of 206.68%. This contributed to the annual value of $67.1 million for FY2024, which is 20.30% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Prepaid Assets is $67.1 million, which was up 20.30% from $55.8 million recorded in FY2023.
  • AbCellera Biologics' 5-year Prepaid Assets high stood at $75.4 million for FY2022, and its period low was $6.0 million during FY2020.
  • Moreover, its 3-year median value for Prepaid Assets was $67.1 million (2024), whereas its average is $66.1 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first skyrocketed by 255.90% in 2021, then dropped by 25.99% in 2023.
  • Over the past 5 years, AbCellera Biologics' Prepaid Assets (Yearly) stood at $6.0 million in 2020, then spiked by 255.90% to $21.2 million in 2021, then skyrocketed by 254.93% to $75.4 million in 2022, then fell by 25.99% to $55.8 million in 2023, then grew by 20.30% to $67.1 million in 2024.